Abstract
Introduction: Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial.
Objectives: We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up.
Methods: This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.
Results: Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages ± SD were 62.3 ± 15.9 years (53.7% male) and 61.9 ± 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort’s rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort’s overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7).
Conclusions: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ.
Keywords: Antimalarial; azithromycin; coronavirus; hydroxychloroquine; macrolide; severe acute respiratory syndrome coronavirus 2.
【저자키워드】 coronavirus, Azithromycin, Macrolide, Hydroxychloroquine, antimalarial, Severe acute respiratory syndrome coronavirus 2., 【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, coronavirus, clinical trial, Azithromycin, Macrolide, Mortality, Hydroxychloroquine, outcome, medications, real-world data, hospitalized patients, severe acute respiratory syndrome Coronavirus, database, antimalarial, arrhythmia, Cohort, male, Patient, age, Hospital admission, HCQ, Follow-up, respiratory, group, Admission, 30-Day mortality, retrospective, Analysis, Odds ratio, on admission, 48 hours, retrospective cohort study, acute respiratory syndrome, Primary outcome, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, 95% confidence interval, overall mortality, no difference, all-cause mortality, measure, off-label, investigated, receiving, increase in, groups, statistically significant, conditions, the mean, statistically, were recorded, 48 hour, diagnosis of COVID-19, patients with COVID-19, 【제목키워드】 Hydroxychloroquine, experience, Assessing,